REGISTRATIONClick here to download the registration form. Please return it with payment to: depression in universities conference Rackham Graduate School, Room 1562, Ann Arbor, Michigan 48109-1070. Register note that before 1 The registration fee is $ 85, after 1 March, the fee increases to $ 100. An additional $ 15 fee applies if you are 22 to lunch on Mar. Want to participate. No registration fee will be charged to the students, doctors in training, and reporters ask if the $ 15 lunch fee. Group bookings are for those who before 1 March Register.

The University of Michigan Medical School this educational activity for a maximum of 12 category 1 credits toward the AMA referred for the doctor Recognition Award. Every doctor should only thus the credits that he / she actually spent in the educational activity.To IDMC stated that the continuation the study was achieve the targeted achieve the desired level of efficiency for use in combination comparing to letrozole alone. To IDMC taken to the conclusion cancer / effectiveness ratio for treatment metastatic breast cancer not in favor of continuation and recommended that the trial be terminated. true are not met, it is unfortunately not unusual for anticancer drugs some cancers and others does not, or even in a few specific subsets in cancer patients working, said Gary L. Executive VP and Chief Medical Officer, Wyeth Pharmaceuticals. We Me obligated. The study of temsirolimus other indications .. The HORIZON studies compared the combination temsirolimus oral tablets and Letrozol compared with letrozole alone.

Wyeth Pharmaceuticals, a division of Wyeth , today announced its decision, that SKYLINES phase 3 clinical trial Programme adjust Wyeth investigational product temsirolimus spoken coated tablets in conjunction with letrozole ), a currently approved breast cancer treatment, for first-line for postmenopausal women having hormone receptor – positive metastatic breast cancer. That decision was , on the recommendation of independent Data Monitoring Committee according to review of data from a planned interim analyzing analysis..